CRISPR Therapeutics Jumps on Takeover Buzz
CRISPR Therapeutics stock surges 6% amid fresh speculation that Vertex Pharmaceuticals may pursue an acquisition.
Already have an account? Sign in.
CRISPR Therapeutics stock surges 6% amid fresh speculation that Vertex Pharmaceuticals may pursue an acquisition.
Nike innovation chief leaves after less than a year amid falling sales, China struggles, and faster rivals; company reshuffles leadership.
Commvault may be sold as buyers show interest. Stock down on AI fears but revenue growing; Thoma Bravo among potential bidders.
FDA again rejects Replimune’s skin cancer drug RP1, saying studies don’t prove it works; shares halted, setback for company.